18F-Florzolotau PET uncovers the Co-pathological Heterogeneity of Tau Protein in Dementia with Lewy Bodies
Objective: We attempted to reveal the topographical deposition patterns of tau proteins in the living brains of patients with DLB in vivo by virtue of…Comparing 18F-AV133 VMAT2 PET and DATscan as Markers of Parkinson’s Disease Severity and Progression
Objective: Compare VMAT2 PET signal with DATscan at baseline and over time, and evaluate their correlations with MDS-UPDRS III. Background: DATscan is a Parkinson’s disease…Association of β-Amyloid Load on PET with Cognitive Profiles Across the Lewy Body Diseases Continuum
Objective: To investigate the association between Aβ accumulation and clinical characteristics across the Lewy body disease (LBD) spectrum, with a specific focus on global and…Differential Diagnosis of Parkinsonism with 18F-FP-CIT PET using a Self-supervised Deep Learning Model
Objective: To develop a self-supervised deep learning model using 18F-FP-CIT PET images from patients with Parkinsonism and to evaluate the model’s performance in the differential…Early Dementia with Lewy Bodies and Parkinson’s Disease with RBD: two faces of the same coin?
Objective: To describe clinical and imaging differences in de novo PD with and without REM sleep Behaviour Disorder (dnPDRBD – de novo PD) and de…Investigating the Use of 18F-DOPA PET/CT to Improve Diagnosis and Clinical Management of Parkinson’s Disease in South Australian Movement Disorder Clinics.
Objective: Evaluate the impact of 18F-DOPA PET/CT on clinical management for Parkinsonism. Background: Parkinson’s Disease affects >100,000 people in Australia with an economic burden of…Brainstem Monoaminergic Degeneration, Cognition, and Autonomic Symptom Progression in Early Parkinson’s Disease
Objective: In this study, we aimed to investigate the association between brainstem monoaminergic nuclear degeneration, particularly the serotonergic raphe and noradrenergic locus coeruleus, and cognitive…Cerebral metabolic network in PLA2G6-associated parkinsonism
Objective: To characterize the cerebral metabolic network in PLA2G6-associated parkinsonism (PLA2G6-P). Background: PLA2G6-associated neurodegeneration is known as a continuum of phenotypes. Patients with late-onset PLA2G6-associated…Bistriatal hypermetabolism on 18-FDG PET-CT in tardive dyskinesia
Objective: Tardive dyskinesia (TD) describes various movement disorders developing after treatment with dopamine receptor blocking agents (DRBA), including stereotypy, akathisia, dystonia, tremor, tics and chorea.…[18F]PR04.MZ PET CT as a clinical tool in the differential diagnosis of PD and other atypical parkinsonian syndromes in the first 5 years of symptoms
Objective: Investigate if the [18F]PR04.MZ PET CT is a useful tool in the differential diagnosis of PD and atypical parkinsonian syndromes (AP), mainly MSA and…
- 1
- 2
- 3
- …
- 33
- Next Page »